Navigation Links
Pharmacyclics Reports Third Quarter 2013 Results
Date:11/7/2013

million for the nine months ended September 30, 2013, compared to $63.4 million for the nine months ended September 30, 2012. During the nine months ended September 30, 2013, the Company recognized $65.9 million of Excess Amounts as a reduction to operating expenses. There were no Excess Amounts recognized for the nine months ended September 30, 2012. Of the Excess Amounts recognized for the nine months ended September 30, 2013, $51.5 million was recorded as a reduction to research and development expenses and $14.4 million was recorded as a reduction to general and administrative expenses.

Under the Agreement, Janssen will fund maximum Excess Amounts of $200 million and $25 million of interest thereon. To date, the Company has recorded Excess Amounts amounting to $84.0 million. The Company recognizes Excess Amounts as a reduction to operating expenses as the Company's repayment of Excess Amounts to Janssen is contingent and would become payable only after the third profitable calendar quarter for the product. Further, Excess Amounts shall be reimbursable only from the Company's share of pre-tax profits (if any) after the third profitable calendar quarter for the product.  

As of September 30, 2013, the Company had cash, cash equivalents and marketable securities of $560.1 million, compared with $317.1 million as of December 31, 2012.

As of September 30, 2013, cash, cash equivalents, marketable securities and accounts receivable from Janssen totaled approximately $612.3 million. The Company now expects to end calendar year 2013 in excess of $600 million in cash, cash equivalents, marketable securities and receivables due from Janssen.

With the progress and achievements to date, the Company expects to be profitable on a GAAP basis for the quarter and year ending December 31, 2013.

"Team Pharmacyclics has consistently improved enrollment and data submission timelines for our CLL and MCL studies over the past years. Often the
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013
2. Pharmacyclics Reports Second Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
4. Pharmacyclics Reports First Quarter 2013 Results
5. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
6. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
7. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
8. Pharmacyclics, Inc. Prices Public Offering of Common Stock
9. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
10. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
11. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... , , VENLO, Netherlands , Feb. 2 QIAGEN N.V. ... financial results call. The Webcast will take place at 9:30 a.m. EST on ... President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer. , ... QIAGEN,s fourth quarter and year-end 2009 financial , ...
... , JERUSALEM , Feb. ... ) announced today the availability of new resources to support ... to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand ... due to inadequate secretion of normal endogenous growth hormone. The ...
Cached Medicine Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 2Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 2Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 4Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 5Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 6
(Date:10/1/2014)... This October, Request A Test , a leading ... 10% off all testing for Diabetes . Customers ... save. The Center for Disease Control (CDC) reports that ... Diabetes. Because many people do not display symptoms, it ... serious health problems. Blood testing can help a person ...
(Date:10/1/2014)... October 01, 2014 After a run ... "Beautiful Births", emerging filmmaker Jacqui Blue is continuing her ... discover the truth about natural birth. The documentary has ... over the world and has been an effective medium ... the topics highlighted in the film provide a wealth ...
(Date:10/1/2014)... 01, 2014 The Oliver Law ... new Other-Sonic Ultrasound Gel lawsuit web page ... the litigation surrounding the 2011 Pseudomonas aeruginosa / ... Royal Oak, Michigan, which was ultimately traced to ... representing William Beaumont patients who allegedly became ill ...
(Date:10/1/2014)... October 01, 2014 Indosoft, Inc., a leading ... announces that it has added support for Sangoma Lyra ... and Indosoft have a history of bringing innovative ... patent-pending technology offers a significant benefit to those using Asterisk ... is now available to users of Q-Suite. , In the ...
(Date:10/1/2014)... 01, 2014 The annual Social Security cost-of-living ... 2015, says a new forecast by The Senior Citizens ... price index (CPI) data through August, TSCL forecasts that COLAs ... the sixth consecutive year of record low COLAs,” states TSCL ... became automatic in 1975,” he notes. , Over the past ...
Breaking Medicine News(10 mins):Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... , TUESDAY, Jan. 24 (HealthDay News) -- People without ... medical care or prescription drugs than people with jobs who ... the depths of the recent recession, unemployment reached 9.6 percent, ... access to care and most people rely on getting insured ...
... , TUESDAY, Jan. 24 (HealthDay News) -- Children with ... gastroesophageal reflux don,t get additional asthma control from acid-reducing ... these medications when there are no digestive issues increases ... the study. "There,s a strong epidemiological link between ...
... , TUESDAY, Jan. 24 (HealthDay News) -- If you have ... of painful flare-ups, new research suggests. The new study ... in the previous four months. They were divided into three ... or skim milk powder enriched with glycomacropeptide (GMP) and G600 ...
... from Rhode Island Hospital reports on the impact to ... upcoming revision to the Diagnostic and Statistical Manual, 5th ... these changes could result in false-negative diagnoses for patients. ... Clinical Psychiatry and is now available online in ...
... announce that it has entered a new long-term collaboration with ... journal Alcohol and Alcoholism . At the end ... the journal Alcohol and Alcoholism , which was previously ... founded in 1967 to improve the understanding and management of ...
... German . Studies currently available provide ... be detected and treated earlier, and consequently tumours occur less ... In this context, an HPV test can be used alone ... both screening procedures also carry a risk of harm in ...
Cached Medicine News:Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 2Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 3Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 2Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 3Health News:Enriched Skim Milk Good for Gout, Study Suggests 2Health News:The impact of deleting 5 personality disorders in the new DSM-5 2Health News:Oxford University Press and Medical Council on Alcohol announce long-term partnership 2Health News:HPV testing: Indications of a benefit in primary screening 2Health News:HPV testing: Indications of a benefit in primary screening 3Health News:HPV testing: Indications of a benefit in primary screening 4
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... The AAFP-PT Laboratory Proficiency Testing and ... programs are designed to assist POLs, clinics ... are designed to assure accuracy of patient ... regulatory requirements. Participation provides the opportunity to ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
Medicine Products: